Leading genomic data management and analytics firm BC Platforms AG has recently announced that the firm has partnered with Medaffcon Oy, a firm that specializes in generating Real World Evidence for making decisions related to health. The alliance is aimed at harmonizing complex clinical and genomic data from numerous sources, jointly applying technological capabilities and specialist knowledge.
Medaffcon’s Medical and Market Access Director, Jaana Ahlamaa, mentioned that the company would be partnering with BC Platforms AG and its leading network of biobanks across the world through its BCRQUEST service. This collaboration would further expand the capabilities of Medaffcon to access and combine various Finnish and international data sources for advancing research.
Tero Silvola, Chief Executive Officer of BC Platforms, was quoted saying that the goal for this partnership is to combine the company’s global platform for leveraging the extensive expertise of Medaffcon in key markets to use the Real World Evidence quicker and with higher effectiveness.
For the record, BC Platforms has over 20 years of experience with information technology and genomics. The company has established a global network of biobanks and provides a safe and secure environment for researchers and biobanks for determining data availability as well as advance research.
The global network of biobanks of BC Platforms, BCRQUEST.COM, allegedly provides clinical and genomic cohort data for medical and pharmaceutical research and development. Medaffcon provides scientific, medical and market access services to the health care operators as well as international pharmaceutical and biotechnology industries.
Medaffcon is owned by the PHOENIX group, a huge integrated European Healthcare provider which ensures that the public and patients have access to high-quality healthcare across the Europe. It has been working as an expert corporation, since its establishment in 2009, with a core competence in health economic and scientific expertise. Since the establishment of Finland’s first biobanks, the company has also been pioneering biobank research efforts driven by industry.